SynthesisJournal of viral hepatitis2025
Risk Factors for Hepatitis C Virus Among the General Population in Sub-Saharan Africa-An Analysis of Systematic Review Data.
Synthesis in Journal of viral hepatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatitis C virus and HIV transmission: parenteral (including percutaneous) routes are still relevant and must receive due attention.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Understanding risk factors for hepatitis C virus (HCV) is critical for targeting screening and prevention. We systematically reviewed risk factors associated with HCV seroprevalence among the general population in sub-Saharan Africa (SSA). Comprehensive systematic review of HCV seroprevalence of community-based observational studies reporting HCV risk factors in SSA. Study quality was assessed using Joanna Briggs Institute tool. Random effect meta-analyses were used to estimate odds ratios (OR) with 95% confidence intervals (CI). We identified 92 studies. Higher odds of HCV seroprevalence were observed among age 21-64 (OR = 1.77, 95% CI 1.17-2.68) and 65+ groups (OR = 11.75, 95% CI 5.51-25.05) compared to those aged ≤ 20 years; not being formally educated (OR = 1.78, 95% CI 1.35-2.35) compared to secondary/above and being married (OR = 1.91, 95% CI 1.45-2.51) or divorced (OR = 3.20, 95% CI 1.91-5.36) compared to never married. Family history of HCV (OR = 1.52, 95% CI 1.17-1.96), being a person living with HIV (OR = 2.64, 95% CI 1.61-4.33) or being HBsAg positive (OR = 1.66, 95% CI 1.10-2.50) were all positively associated with increased HCV seroprevalence, as was having a history of blood transfusion (OR = 1.81, 95% CI 1.33-2.45), hospitalisation (OR = 1.55, 95% CI 1.22-1.96), medical operation (OR = 1.28, 95% CI 1.01-1.62), scarification (OR = 1.29, 95% CI 1.01-1.64) and injection drug use (OR = 7.04, 95% CI 1.16-42.68). Pilot HCV screening programmes targeting older adults and people exposed to healthcare-associated factors could potentially lead to the efficient detection of HCV cases and reduce future HCV exposures among the general population in SSA countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.